FRG-8813

Known as: FRG 8813 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2002
2002
Lafutidine (FRG-8813) is a new H2-receptorantagonist that not only has a strong inhibitory effect on gastric secretion but also… (More)
Is this relevant?
2001
2001
Lafutidine (FRG-8813) is a new H2-receptorantagonist that not only has a strong inhibitory effect on gastric secretion but also… (More)
Is this relevant?
2000
2000
We investigated the recurrence of ulcers in rats after treatment with FRG-8813, (+/-)-2-(furfurylsulfinyl)-N-[4- [4… (More)
Is this relevant?
1998
1998
The effects of a novel histamine H2 receptor antagonist (FRG-8813) on the restoration process of gastric epithelial wounds were… (More)
  • table 1
  • table 2
Is this relevant?
1998
1998
Although the new histamine H2 receptor antagonist, lafutidine (FRG-8813), N-[4-[4-(piperidinylmethyl)pyridyl-2-oxy]-(Z)-2-butenyl… (More)
Is this relevant?
1996
1996
Certain chemical properties, which may determine the stimulatory actions of the new histamine H2 receptor antagonist, FRG-8813 (2… (More)
Is this relevant?
1994
1994
It is not presently well understood whether the histamine H2 receptor antagonist has a function other than the inhibition of… (More)
Is this relevant?
1994
1994
The effects of the anti-acid secretory agents, cimetidine (N-cyano-N'-methyl-N"-(2-([(5-methyl-1H-imidazol-4-yl)methyl]thio)ethyl… (More)
Is this relevant?
1992
1992
We examined the anti-ulcer effects of FRG-8813, a new type histamine H2-receptor antagonist, on various experimental gastric and… (More)
Is this relevant?